Browsing by Author Keech, Anthony (Tony)

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 20 of 124  next >
Issue DateTitleAuthor(s)Citation
2010Ability of traditional lipid ratios and apolipoprotein ratios to predict cardiovascular risk in people with type 2 diabetesBarter, Philip; Keech, Anthony (Tony); Mann, Kirsty; Simes, Robert John; Best, J; Ehnholm, Christian; Hamwood, S; Sullivan, David Richmond; Taskinen, M.; Central Clinical School: Heart Research Institute; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentreAbility of traditional lipid ratios and apolipoprotein ratios to predict cardiovascular risk in people with type 2 diabetes, Diabetologia: clinical and experimental diabetes and metabolism, vol.53, 9,pp 1846-1855
2007Abstract 3691: Features Of Metabolic Syndrome Identify Individuals With Type 2 Diabetes Mellitus At High Risk For Cardiovascular Events And Greater Absolute Benefits Of FenofibrateBarter, Philip; Copt, Samuel; Keech, Anthony (Tony); Pardy, Christopher; Best, James; D'Emden, Michael C.; Drury, P; Ehnholm, Christian; FIELD study investigators, Fenofibrate Intervention and Event Lowering in Diabetes; Kesaniemi, Y. Antero; Scott, Russell; Taskinen, M.; Tse, Dana; Central Clinical School: Heart Research Institute; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentreAbstract 3691: Features Of Metabolic Syndrome Identify Individuals With Type 2 Diabetes Mellitus At High Risk For Cardiovascular Events And Greater Absolute Benefits Of Fenofibrate, Circulation (Baltimore), vol.116, N/A,pp II_838-N/A
2005Allocation concealment and blinding [reply]Forder, Peta; Gebski, Val; Keech, Anthony (Tony); School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentreAllocation concealment and blinding [reply], Medical Journal of Australia, vol.183,(3),2005,pp 165-166
2003Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatmentKeech, Anthony (Tony); Frohlich, J; Furberg, C; Jungner, I; Roeters van Lennep, J E; Sniderman, A D; Walldius, G; School of Public Health: NH&MRC Clinical Trials CentreApolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment, The Lancet, vol.361,(9359),2003,pp 777-780
2014Association of Contemporary Sensitive Troponin I Levels at Baseline and Change at 1 Year With Long - Term Coronary Events Following Myocardial Infarction or Unstable AnginaKeech, Anthony (Tony); Mann, Kristy; Simes, Robert John; Blankenberg, Stefan; Colquhoun, David; Hunt, David; Nestel, Paul; Stewart, Ralph A.H.; Sullivan, David; Thompson, Peter; Tonkin, Andrew; West, Malcolm; White, Harvey D.; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentreAssociation of Contemporary Sensitive Troponin I Levels at Baseline and Change at 1 Year With Long - Term Coronary Events Following Myocardial Infarction or Unstable Angina, Journal of the American College of Cardiology, vol.63, 4, 2014,pp 345-354
2011Associations between the use of metformin, sulphonylureas, or diet alone and cardiovascular outcomes in 6005 patients with type 2 diabetes in the FIELD studyDonoghoe, Mark; Forder, Peta; Keech, Anthony (Tony); Kritharides, Leonard; Merrifield, Alistair; Simes, Robert John; Sullivan, David; Colman, P. G.; Haapamäki, Hannu; Neil, Graham; Whiting, Malcolm; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; Concord Clinical School: ANZAC Research Institute; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; Molecular BioscienceAssociations between the use of metformin, sulphonylureas, or diet alone and cardiovascular outcomes in 6005 patients with type 2 diabetes in the FIELD study, Diabetes Research and Clinical Practice, vol.94, 2, 2011,pp 284-290
2013Balloon Warming Time Is the Strongest Predictor Of Late Pulmonary Vein Electrical Reconnection Following Balloon Cryoablation for Atrial FibrillationKeech, Anthony (Tony); Martin, Andrew; Chan, Kim; Ghosh, Justin; Gomes, Sean; McGuire, Mark; Singarayar, Suresh; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentreBalloon Warming Time Is the Strongest Predictor Of Late Pulmonary Vein Electrical Reconnection Following Balloon Cryoablation for Atrial Fibrillation, Heart Rhythm, vol.10, 9, 2013,pp 1311-1317
2017Baseline circulating FGF21 concentrations and increase after fenofibrate treatment predict more rapid glycemic progression in type 2 diabetes: Results from the FIELD studyBarter, Philip; Januszewski, Andrzej Szczesny; Jenkins, Alicia; Keech, Anthony (Tony); O'Connell, Rachel; Ong, Kwok; Rye, Kerry-Anne; Simes, Veronica; Sullivan, David; Waldman, Boris; Best, J; Colman, P; Scott, R; Taskinen, Marja-Riitta; Xu, A; Central Clinical School: Heart Research Institute; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; Central Clinical School: Heart Research Institute; Central Clinical School: Heart Research Institute; Plant & Food Sciences; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials CentreBaseline circulating FGF21 concentrations and increase after fenofibrate treatment predict more rapid glycemic progression in type 2 diabetes: Results from the FIELD study, Clinical Chemistry, vol.63, 7, 2017,pp 1261-1270
2016Beta-blocker, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker, nitrate-hydralazine, diuretics, aldosterone antagonist, ivabradine, devices and digoxin (BANDAID2): An evidence-based mnemonic for the treatment of systolic heart failureChia, Nicole; Fulcher, Jordan; Keech, Anthony (Tony); Childrens Hospital Westmead: Paediatrics & Child Health; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials CentreBeta-blocker, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker, nitrate-hydralazine, diuretics, aldosterone antagonist, ivabradine, devices and digoxin (BANDAID2): An evidence-based mnemonic for the treatment of systolic heart failure, Internal Medicine Journal, vol.46, 6, 2016,pp 653-662
2007Biases in the Identification of Risk Factor Thresholds and J-CurvesKeech, Anthony (Tony); Marschner, Ian; Simes, Robert John; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentreBiases in the Identification of Risk Factor Thresholds and J-Curves, American Journal of Epidemiology, vol.166,(7),2007,pp 824-831
2015Biomarkers in Diabetic RetinopathyHardikar, Anandwardhan; Januszewski, Andrzej Szczesny; Jenkins, Alicia; Joglekar, Mugdha; Keech, Anthony (Tony); O'Neal, David; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials CentreBiomarkers in Diabetic Retinopathy, The Review of Diabetic Studies, vol.12, 1-2, 2015,pp 159-195
2015Biomarkers in stable coronary heart disease, their modulation and cardiovascular risk: The LIPID biomarker studyHague, Wendy; Keech, Anthony (Tony); Kirby, Adrienne; Simes, Robert John; Sullivan, David; Blankenberg, Stefan; Colquhoun, David; Funke-Kaiser, Anne; Hunt, David; Nestel, P; Stewart, Ralph; Thompson, Peter; Tonkin, Andrew; West, Malcolm; White, Harvey; Zeller, Tanja; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials CentreBiomarkers in stable coronary heart disease, their modulation and cardiovascular risk: The LIPID biomarker study, International Journal of Cardiology, vol.201, N/A, 2015,pp 499-507
2008Can self-rated health scores be used for risk prediction in patients with type 2 diabetes?Clarke, Philip; Hayes, Alison; Keech, Anthony (Tony); Simes, Robert John; Drury, P; Glasziou, Paul; School of Public Health: Public Health; School of Public Health: Public Health; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentreCan self-rated health scores be used for risk prediction in patients with type 2 diabetes?, Diabetes Care, vol.31, 4, 2008,pp 795-797
2017Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trialKeech, Anthony (Tony); De Ferrari, Gaetano M; Deedwania, Prakash; et al, Various; Giugliano, Robert P; Gouni-Berthold, Ioanna; Kuder, J; Leiter, Lawrence A.; Murphy, Sabina A.; Sabatine, Marc S.; Wiviott, S; NH&MRC Clinical Trials CentreCardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial, The Lancet Diabetes & Endocrinology, vol.5, 12, 2017,pp 941-950
2013Changes in lipoprotein-associated phospholipase A2 activity predict coronary events and partly account for the treatment effect of pravastatin: results from the Long-Term Intervention with Pravastatin in Ischemic Disease studyBarnes, Elizabeth; Keech, Anthony (Tony); Marschner, Ian (Colin); Simes, Robert John; Sullivan, David; Blankenberg, Stefan; Colquhoun, David; Hunt, David; Nestel, Paul; Stewart, Ralph A.H.; Thompson, Peter; Tonkin, Andrew; West, Malcolm; White, Harvey D.; Zeller, Tanja; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentreChanges in lipoprotein-associated phospholipase A2 activity predict coronary events and partly account for the treatment effect of pravastatin: results from the Long-Term Intervention with Pravastatin in Ischemic Disease study, Journal of the American Heart Association, vol.2, 5, 2013,pp 1-12
2014Cigarette smoking and albuminuria are associated with impaired arterial smooth muscle function in patients with type 2 diabetes mellitus: a FIELD substudyCelermajer, David; Harmer, Jason; Keech, Anthony (Tony); Skilton, Michael; Veillard, Anne-Sophie; Marwick, Thomas H; Meredith, Ian T; Watts, Gerald F; Central Clinical School: Medicine; Central Clinical School: Medicine; School of Public Health: NH&MRC Clinical Trials Centre; Boden Institute; School of Public Health: NH&MRC Clinical Trials CentreCigarette smoking and albuminuria are associated with impaired arterial smooth muscle function in patients with type 2 diabetes mellitus: a FIELD substudy, Diabetes Research and Clinical Practice, vol.106, 2, 2014,pp 328-336
2017Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trialKeech, Anthony (Tony); Ceska, Richard; De Ferrari, Gaetano M; et al, Various; Gaciong, Zbigniew A; Giugliano, Robert P; Gouni-Berthold, Ioanna; Lopez-Miranda, Jose; Park, Jeong-Gun; Pedersen, Terje R; Toth, Kalman; NH&MRC Clinical Trials CentreClinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial, The Lancet, vol.390, 10106, 2017,pp 1962-1971
2017Clinical efficacy and safety of evolocumab in high-risk patients receiving a statin: Secondary analysis of patients with low LDL cholesterol levels and in those already receiving a maximal-potency statin in a randomized clinical trialKeech, Anthony (Tony); Ferreira, Jorge; Giugliano, Robert P; Huber, Kurt; Lewis, Basil S.; Murphy, S; Pedersen, T; Pineda, Armando Lira; Sabatine, Marc S.; Sever, Peter; Somaratne, Ransi; Tokgozoglu, S. Lale; NH&MRC Clinical Trials CentreClinical efficacy and safety of evolocumab in high-risk patients receiving a statin: Secondary analysis of patients with low LDL cholesterol levels and in those already receiving a maximal-potency statin in a randomized clinical trial, JAMA Cardiology, vol.2, 12, 2017,pp 1385-1391
2015Clinical Guidelines on Hyperlipidaemia: Recent Developments, Future Challenges and the Need for an Australian ReviewChow, Clara Kayei; Keech, Anthony (Tony); Barter, Philip; Grenfell, Robert; Nicholls, Stephen; Sullivan, D; Tonkin, Andrew M; Watts, Gerald F; Western Clinical School: Medicine (Westmead); NH&MRC Clinical Trials CentreClinical Guidelines on Hyperlipidaemia: Recent Developments, Future Challenges and the Need for an Australian Review, Heart, Lung and Circulation, vol.24, 5, 2015,pp 495-502
2003Clinical trials research in the new millennium: the International Clinical Trials Symposium, Sydney, 21-23 October 2002Keech, Anthony (Tony); Simes, Robert John; Pike, R; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentreClinical trials research in the new millennium: the International Clinical Trials Symposium, Sydney, 21-23 October 2002, Medical Journal of Australia, vol.178,(7),2003,pp 316-317